Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the APMA Annual Meeting

Viamet Pharmaceuticals, Inc. today announced that Chief Development Officer, Amir Tavakkol, Ph.D., Dip. Bacteriol, will present data from the Company’s VT-1161 therapeutic program in the treatment of onychomycosis, or fungal nail infection, at the American Podiatric Medical Association (APMA) 2017 Annual Scientific Meeting (The National), being held July 27 – 30 in Nashville, TN. The poster will include results and conclusions from Viamet’s successful Phase 2b RENOVATE study for VT-1161, the Company’s novel inhibitor of fungal CYP51, in the treatment of moderate-to-severe distal-lateral subungual onychomycosis.